Icatibant Hikma

Icatibant, the active ingredient in Icatibant Hikma, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema attacks in patients with hereditary angioedema types I and II, providing rapid symptom relief. The drug is authorized in the European Union and is supplied in single‑use prefilled syringes.

GNH USA supplies Icatibant Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a bradykinin B2 receptor antagonist used to manage hereditary angioedema attacks.

- Hereditary angioedema type I: rapidly reduces swelling and associated pain. - Hereditary angioedema type II: alleviates acute episodes of edema. - Hereditary angioedema with normal C1‑INH: provides symptom control during attacks.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or erythema: localized skin irritation. - Swelling at injection site: mild to moderate edema. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, itching, or hives. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Airway angioedema: swelling that may compromise breathing. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, clinicians should consider several safety measures.

- Verify diagnosis: confirm hereditary angioedema type before administration. - Assess allergy history: avoid in patients with known hypersensitivity to icatibant. - Monitor for reactions: observe for signs of hypersensitivity during and after injection. - Caution with ACE inhibitors: increased bradykinin levels may augment adverse effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin pathway or cardiovascular status.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema. - Other bradykinin B2 antagonists: concurrent use can lead to unpredictable pharmacodynamics.

Moderate Interactions (Monitor Closely): - Neprilysin inhibitors: potential additive effect on bradykinin activity. - Diuretics: may affect blood pressure response; monitor hemodynamics.